Core Viewpoint - X4 Pharmaceuticals has initiated an underwritten public offering of its common stock and pre-funded warrants, aiming to raise funds for the development of mavorixafor and other corporate purposes [1][2]. Group 1: Offering Details - The public offering includes an option for underwriters to purchase an additional 15% of the shares offered at the public offering price [1]. - The offering is subject to market conditions, and there is no guarantee regarding its completion or the terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to the pivotal Phase 3 development of mavorixafor for chronic neutropenic disorders, as well as for general administrative expenses, capital expenditures, and working capital [2]. Group 3: Company Background - X4 Pharmaceuticals focuses on developing therapies for rare hematology diseases, with mavorixafor being a key product currently marketed in the U.S. as XOLREMDI® [5]. - The company is conducting a global pivotal Phase 3 clinical trial (4WARD) for mavorixafor in patients with chronic neutropenic disorders [5].

Core Insights - X4 Pharmaceuticals will report its financial results for Q1 2025 on May 1, 2025, and provide corporate updates [1] - A conference call and webcast will be held on the same day at 8:30 a.m. EDT for investors [2] Company Overview - X4 Pharmaceuticals focuses on developing innovative therapies for rare immune system diseases with significant unmet needs [3] - The company has developed mavorixafor, an orally available CXCR4 antagonist, currently marketed in the U.S. as XOLREMDI® [3] - X4 is conducting a global pivotal Phase 3 clinical trial (4WARD) for mavorixafor in patients with certain chronic neutropenic disorders [3]

Core Viewpoint - X4 Pharmaceuticals has announced a one-for-thirty reverse stock split to address compliance issues with Nasdaq's minimum bid price requirement and to potentially increase the market price of its Common Stock [1][11]. Summary by Sections Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern Time on April 28, 2025, with trading on a split-adjusted basis commencing on the same day [2]. - The split will consolidate every thirty shares into one, reducing the number of outstanding shares from approximately 173.6 million to about 5.8 million [3]. - Proportional adjustments will be made to equity incentive plans, stock options, and outstanding warrants in accordance with the reverse stock split [4]. Shareholder Impact - No fractional shares will be issued; instead, shareholders entitled to fractional shares will receive cash [5]. - Stockholders with shares held in book-entry form or through intermediaries will see the effects of the reverse stock split reflected in their accounts without needing to take action [6]. Compliance with Nasdaq - The reverse stock split was approved within the range disclosed at the 2025 Special Meeting of Stockholders held on April 17, 2025 [7]. - X4 received a deficiency letter from Nasdaq due to its stock price falling below the required minimum of $1.00 per share for 30 consecutive business days [8]. - The company was granted an additional 180-day compliance period until August 11, 2025, to regain compliance with the Bid Price Rule [10]. Company Strategy - X4 believes that the reverse stock split will help increase the market price of its Common Stock and address the deficiency in the Bid Price Rule [11].